KC
FLACU

KCL Capital’s Frazier Lifesciences Acquisition Corporation Unit FLACU Stock Holding History

KCL Capital’s Portfolio FLACU Stock Details FLACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$208K – 110
2020
Q4 		$208K Buy
+20,000
New +$209K 0.02% 109

Other funds holding FLACU

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

KCL Capital's FLACU Position: Q1 2021 in Review

KCL Capital sold out of Frazier Lifesciences Acquisition Corporation Unit (FLACU) in Q1 2021, closing a stake of 20,000 shares — an estimated $208K sold.

KCL Capital first reported a position in FLACU in Q4 2020 and held it in 1 quarter. The position peaked at $208K in Q4 2020. 37 funds tracked by Wall St. Rank hold FLACU as of Q1 2021.

  • KCL Capital reported no remaining Frazier Lifesciences Acquisition Corporation Unit position as of Q1 2021 after selling out during the quarter.
  • KCL Capital sold 20,000 Frazier Lifesciences Acquisition Corporation Unit shares in Q1 2021, an estimated $208K.
  • KCL Capital first reported a position in Frazier Lifesciences Acquisition Corporation Unit in Q4 2020 and held it in 1 quarter.
  • KCL Capital's Frazier Lifesciences Acquisition Corporation Unit position peaked at $208K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Unit as of Q1 2021.

Based on KCL Capital's 13F filing for Q1 2021, filed 17 May 2021.